News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals to Present at Two Investor Conferences in March
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 5, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update
Conference Call and Webcast Today, February 25 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Feb. 25, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 19, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant)
Phase 2 Clinical Study Initiating Later in First Quarter 2019 DURHAM, N.C. --(BUSINESS WIRE)--Jan. 17, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan
Announces Opening of Tokyo Branch Office and Two Key Hires in Japan DURHAM, N.C. --(BUSINESS WIRE)--Jan. 4, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access
DURHAM, N.C. --(BUSINESS WIRE)--Jan. 2, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 7, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Conference Call and Webcast Today, November 6 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Nov. 6, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 30, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018 . Following the release, the Company will host a live
View HTML
Toggle Summary Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters
The Company now occupies more than 60,000 sq. ft. of laboratory and office space at the Durham, North Carolina , facility DURHAM, N.C. --(BUSINESS WIRE)--Oct. 23, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and
View HTML
TOP